Cart
sales@molnova.com
AST-1306
CAS No. 1050500-29-2
AST-1306 ( —— )
Catalog No. M10245 CAS No. 1050500-29-2
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 335 | In Stock |
|
| 50MG | 500 | In Stock |
|
| 100MG | 705 | In Stock |
|
| 500MG | 1485 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAST-1306
-
NoteResearch use only, not for human use.
-
Brief DescriptionAST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
-
DescriptionAST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases,
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1050500-29-2
-
Formula Weight621.08
-
Molecular FormulaC31H26ClFN4O5S
-
Purity>98%(HPLC)
-
SolubilityDMSO:124 mg/mL (199.65 mM); Ethanol:<1 mg/mL (<1 mM); Water：<1 mg/mL (<1 mM)
-
SMILESCC1=CC=C(C=C1)S(O)(=O)=O.FC1=CC(COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl)=CC=C1 |c:3,5,22,31,34,36,39,42,44,t:1,12,17,19,24|
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xie H, et al. PLoS One. 2011, 6(7), e21487.
molnova catalog
related products
-
Afatinib
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
Orphenadrine Citrate
Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
